{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-017473","form_type":"8-K","ticker":"APVO","cik":"0001671584","company_name":"Aptevo Therapeutics Inc.","filed_at":"2025-02-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.386393+00:00","generated_at":"2026-05-26T23:24:35.898268+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"medium","headline":"Aptevo Therapeutics provides pipeline update via investor presentation","bullets":["Presentation highlights clinical candidates mipletamig and ALG.APV-527.","Preclinical candidates APVO711, APVO603, APVO442 are also detailed.","No new clinical data, trial results, or financial guidance provided.","Presentation dated February 11, 2025, furnished under Regulation FD."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-017473","json":"https://secwatch.observer/filing/0000950170-25-017473.json","markdown":"https://secwatch.observer/filing/0000950170-25-017473.md","text":"https://secwatch.observer/filing/0000950170-25-017473.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671584/000095017025017473/0000950170-25-017473-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671584/000095017025017473/apvo-20250211.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T23:24:35.898268+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}